Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04737187 · ClinicalTrials.gov registry record · Phase 3
Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients
A Phase 3 study of Refractory Metastatic Colorectal Cancer, sponsored by Taiho Oncology.
- Completed
- Registry status
- Phase 3
- Development phase
- 492
- Enrollment target
- 20
- Study locations
NCT04737187: Completed Phase 3 study of Refractory Metastatic Colorectal Cancer, sponsored by Taiho Oncology.
NCT04737187 is a Phase 3 study of Refractory Metastatic Colorectal Cancer that has completed, run by Taiho Oncology. The registered enrollment target is 492 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (36% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04737187, a Phase 3 study of Refractory Metastatic Colorectal Cancer, has completed, sponsored by Taiho Oncology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 492 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is designed as an international, open-label, controlled two-arm, randomized phase III comparison study evaluating the efficacy and safety of trifluridine/tipiracil in combination with bevacizumab versus trifluridine/tipiracil monotherapy in patients with refractory mCRC.
Primary Outcome
Overall survival defined as the observed time elapsed between the date of randomization and the date of death due to any cause. The primary estimand of interest was defined to assess the effect of the randomized treatments on the survival duration in all participants regardless of whether or not intercurrent events had occurred (treatment policy strategy). Analysis was performed using Kaplan- Meier method.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Trifluridine/Tipiracil
Study Locations (20)
Other
- "Medizinische Universität Graz " - Graz
- "Medizinische Universität Innsbruck Univ.-Klinik für Innere Medizin V" - Innsbruck
- "Ordensklinikum Linz Barmherzige Schwestern Interne I" - Linz
- "Landeskrankenhaus Feldkirch Interne E" - Rankweil
- "Landeskrankenhaus (SALK) Universitätsklinik für Innere Medizin III (SALK)" - Salzburg
- "Allgemeines Krankenhaus - Universitätskliniken Klinische Abteilung für Onkologie" - Vienna
- "Landesklinikum Wiener Neustadt " - Wiener Neustadt
- "OLV Ziekenhuis Oncology" - Aalst
California
- City of Hope - Duarte
- City of Hope - South Pasedena - South Pasadena
- City of Hope - Upland - Upland
Florida
- Mayo Clinic - FL - Jacksonville
- Mount Sinai Comprehensive Cancer Center - Miami Beach
- Comprehensive Hematology Oncology - St. Petersburg
Arizona
- Mayo Clinic Hospital - Phoenix
Illinois
- DuPage Medical Group - Joliet Oncology-Hematology Associates - Joliet
Indiana
- Investigative Clinical Research of Indiana LLC - Noblesville
Nebraska
- Oncology Hematology West, PC dba Nebraska Cancer Specialists - Omaha
New York
- Mayo Clinic - Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 492 participants |
| Start Date | 2020-11-25 |
| Est. Completion | 2023-09-12 |
| Phase | Phase 3 |
What the finished NCT04737187 record still lists
NCT04737187 is an interventional study that assigns participants to a tested intervention. The registered 492 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (36% lower).
The record links to 1 condition, with Refractory Metastatic Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Bevacizumab is the first listed.
NCT04737187 names 20 study sites across 9 states, led by Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT04737187 about?
NCT04737187 is a clinical study titled "Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients". This study is designed as an international, open-label, controlled two-arm, randomized phase III comparison study evaluating the efficacy and safety of trifluridine/tipiracil in combination with bevacizumab versus trifluridine/tipiracil monotherapy in patients with refractory mCRC.
What is the current status of trial NCT04737187?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 492 participants. The study started on 2020-11-25. Estimated completion is 2023-09-12.
What conditions does trial NCT04737187 study?
This clinical trial studies the following conditions: Refractory Metastatic Colorectal Cancer.
What interventions are being tested in trial NCT04737187?
The interventions under investigation include: Bevacizumab (DRUG), Trifluridine/Tipiracil (DRUG).
Who is sponsoring clinical trial NCT04737187?
This trial is sponsored by Taiho Oncology, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04737187 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Metastatic Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04737187's enrollment target sits among peer trials
492 780th of 2000 higher than 1,220 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05861973 · 492 participants · NA
SMARTer Weight Loss Management
- NCT05908331 · 492 participants · NA
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
- NCT06152575 · 492 participants · Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- NCT06953089 · 492 participants · Phase 2
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI